Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma

Clinically, human glioblastoma (GBM) may develop de novo or from a low-grade glioma (secondary GBM), and molecular alterations in the two pathways may differ. This study examined the status of Survivin expression and apoptosis in 30 primary and 26 secondary GBMs. Our results show that cytoplasmic Survivin positivity was significantly (P<0.001) more frequent in primary GBMs (83%) than that in secondary GBMs (46%). In addition, an inverse correlation of cytoplasmc Survivin positivity with GBM apoptotic index, and a positive association between cytoplasmic Survivin and size of the tumours were observed. These results suggest that cytoplasmic Survivin, via its antiapoptotic function, may be involved in the tumorigenesis of many primary GBMs, but only in a small fraction of secondary GBMs. Furthermore, the overall progression times from low-grade precursor lesions to secondary GBMs were significantly shorter (P<0.05) in cytoplasmic Survivin-positive cases (mean, 15.6 months) than those in Survivin-negative cases (mean, 23.8 moths), and the positive expression level of Survivin in cytoplasm was upregulated in most secondary GBMs when compared to matched pre-existing low-graded lesions. These results suggest that the increased accumulation of Survivin in the cytoplasm of more malignant glioma cells may prove to be a selective advantage, thus accelerating progression to a more aggressive phenotype.

[1]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[2]  H. Stein,et al.  Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma , 2003, British Journal of Cancer.

[3]  A. Das,et al.  Expression of survivin in primary glioblastomas , 2002, Journal of Cancer Research and Clinical Oncology.

[4]  Y. Tao,et al.  Amplification and overexpression of epidermal growth factor receptor gene in glioblastomas of Chinese patients correlates with patient’s age but not with tumor’s clinicopathological pathway , 2005, Acta Neuropathologica.

[5]  S. Moriyama,et al.  Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy , 2001, International journal of cancer.

[6]  C. Marosi,et al.  No prognostic impact of survivin expression in glioblastoma , 2005, Acta Neuropathologica.

[7]  K. Shroyer,et al.  Survivin in glioblastomas. Protein and messenger RNA expression and comparison with telomerase levels. , 2003, Archives of pathology & laboratory medicine.

[8]  F. Davis,et al.  The conditional probability of survival of patients with primary malignant brain tumors , 1999, Cancer.

[9]  Y. Yonekawa,et al.  Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas , 2000, Journal of neuropathology and experimental neurology.

[10]  E. Nigg,et al.  Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. , 2003, Molecular biology of the cell.

[11]  C. Suschek,et al.  Differential subcellular localization of functionally divergent survivin splice variants , 2002, Cell Death and Differentiation.

[12]  D. Altieri,et al.  A p34(cdc2) survival checkpoint in cancer. , 2002, Cancer cell.

[13]  Y. Takano,et al.  Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. , 2001, Cancer letters.

[14]  L. O’Driscoll,et al.  Prognostic importance of survivin in breast cancer , 2003, British Journal of Cancer.

[15]  D. Boue,et al.  Nuclear expression of Survivin in paediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade , 2003, British Journal of Cancer.

[16]  Kouji Matsumoto,et al.  Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index , 2005, Journal of Neuro-Oncology.

[17]  H. J. Kim,et al.  An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. , 2001, Biochemistry.

[18]  D. Vaux,et al.  Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype , 2000, Current Biology.

[19]  E. Felip,et al.  A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Sugimori,et al.  Apoptotic index in ovarian carcinoma: correlation with clinicopathologic factors and prognosis. , 1997, Gynecologic oncology.

[21]  K. Sasaki,et al.  Intratumoral cytogenetic heterogeneity detected by comparative genomic hybridization and laser scanning cytometry in human gliomas. , 1998, Cancer research.

[22]  D. Altieri,et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. , 1998, Cancer research.

[23]  K. Shroyer,et al.  Survivin expression in human osteosarcoma is a marker for survival. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  D. Xie,et al.  Heterogeneous expression and association of β‐catenin, p16 and c‐myc in multistage colorectal tumorigenesis and progression detected by tissue microarray , 2003, International journal of cancer.

[25]  P. Black,et al.  Quantitatively determined survivin expression levels are of prognostic value in human gliomas. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Tsutomu Sasaki,et al.  Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system , 2002, Acta Neuropathologica.

[27]  Y. Yonekawa,et al.  Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. , 1996, Brain pathology.

[28]  J. Diebold,et al.  Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. , 1998, The American journal of pathology.